American International Group, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

American International Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$40.88 - $43.27 $22,320 - $23,625	546 Added 1.57%	35,294 $1.49 Million
Q4 2023 Feb 13, 2024	BUY	$20.27 - $42.44 $78,343 - $164,030	3,865 Added 12.51%	34,748 $1.47 Million
Q3 2023 Nov 13, 2023	BUY	$20.26 - $31.91 $22,245 - $35,037	1,098 Added 3.69%	30,883 $674,000
Q2 2023 Aug 04, 2023	BUY	$23.9 - $35.38 $51,050 - $75,571	2,136 Added 7.73%	29,785 $946,000
Q1 2023 May 12, 2023	BUY	$22.82 - $35.32 $12,551 - $19,426	550 Added 2.03%	27,649 $674,000
Q4 2022 Feb 10, 2023	BUY	$25.35 - $31.96 $32,929 - $41,516	1,299 Added 5.03%	27,099 $854,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $9,307 - $15,118	365 Added 1.44%	25,800 $729,000
Q2 2022 Aug 12, 2022	BUY	$20.62 - $37.15 $107,409 - $193,514	5,209 Added 25.75%	25,435 $673,000
Q1 2022 May 13, 2022	SELL	$23.5 - $35.38 $33,440 - $50,345	-1,423 Reduced 6.57%	20,226 $708,000
Q4 2021 Feb 11, 2022	SELL	$29.21 - $44.64 $8,470 - $12,945	-290 Reduced 1.32%	21,649 $702,000
Q3 2021 Nov 12, 2021	BUY	$21.26 - $38.85 $46,346 - $84,693	2,180 Added 11.03%	21,939 $647,000
Q2 2021 Aug 13, 2021	BUY	$12.56 - $29.69 $248,173 - $586,644	19,759 New	19,759 $506,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.